Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.

Syndax’s Revuforj beats Kura in NPM1-mutated AML.

As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?

But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.

FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.